Cart
sales@molnova.com
Sarracenin
CAS No. 59653-37-1
Sarracenin( —— )
Catalog No. M24593 CAS No. 59653-37-1
Sarracenin is a natural product. Sarracenin shows cytotoxic activities against tumor cells.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 138 | In Stock |
|
| 5MG | 147 | In Stock |
|
| 10MG | 217 | In Stock |
|
| 25MG | 370 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameSarracenin
-
NoteResearch use only, not for human use.
-
Brief DescriptionSarracenin is a natural product. Sarracenin shows cytotoxic activities against tumor cells.
-
DescriptionSarracenin is a natural product. Sarracenin shows cytotoxic activities against tumor cells.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorOthers
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number59653-37-1
-
Formula Weight226.22
-
Molecular FormulaC11H14O5
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESCC(C1C2C3)OC3OC1OC=C2C(OC)=O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Iridoid Glucosides from Chinese Herb Lonicera chrysatha and Their Antitumor Activity.Journal of Chemical Research,2003(10):676-677.
molnova catalog
related products
-
RMC-6291
RMC-6291 is an orally active, covalent inhibitor of KRAS G12C (ON) that forms a tri-complex within tumor cells between KRAS G12C (ON) and cyclophilin A (CypA), thereby preventing KRAS G12C (ON) from signaling via steric blockade of RAS effector binding and eliciting deep and durable suppression of RAS pathway activity in KRAS G12C tumor models .
-
Massonianoside D
The herbs of Pinus yunnanensis.
-
Vina-ginsenoside R8
Vinaginsenoside R8, a triterpenoid glycoside isolated from the rhizomes of Panacis majoris. Vinaginsenoside R8 displays activities against adenosine diphosphate (ADP)-induced platelet aggregation (IC50=25.18 μM).
